JAZZ News and Press, Jazz Pharmaceuticals plc From 05/05/20

Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q1 Non-GAAP EPS of $0.45 misses by $0.38 ; GAAP EPS of -$2.82 misses by $1.72 . Revenue of $534.73M (+5.2% Y/Y) misses by $9.82M . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news,

Total Revenues Increased 5% to $535 Million Compared to First Quarter 2019 Strong Xyrem Net Revenues of $408 Million , an Increase of 11% Compared to First Quarter 2019 Cash from Operations Exceeded $270 Million ; Cash and Investments of $1 Billion at Quarter End Received ...

It's time to shop for healthcare stocks that have suffered so far this year but should rebound in the long term thanks to growth drivers waiting in the wings. The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible ...

Moderna Boosts Production with Lonza Deal Moderna Therapeutics ( MRNA ) announced its new collaboration with Lonza for boosting its production capacity for mRNA 1273. The company had recently struck a deal with the federal government to focus on developing COVID 19 vaccine candidate. ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) slips  3%  premarket on light volume on the heels of disappointing results from a Phase 3 clinical trial evaluating defibrotide for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem-cell transplantation (HSCT) i...

DUBLIN , April 29, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-ris...

Jazz Pharmaceuticals (NASDAQ: JAZZ) has witnessed stellar growth of Xyrem for the treatment of narcolepsy since its launch. Sales of the product have amounted to over $1 billion and are increasing rapidly. The momentum , however, relies solely on the drug's market exclusivity, which may be ...

Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) were skyrocketing 24.9% as of 11:19 a.m. EDT on Monday. The big jump came after the drugmaker announced positive results from a late-stage study evaluating the once-nightly sodium oxybate drug FT218 in treating excessive daytime sleepiness and ...

Avadel Pharmaceuticals (NASDAQ: AVDL ) jumps  30%  premarket on average volume in reaction to positive results from a Phase 3 clinical trial, REST-ON , evaluating lead candidate FT218, a once-nightly formulation of sodium oxybate, for the treatment of excessive daytime sleepines...

DUBLIN , April 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 first quarter financial results on Tuesday, May 5, 2020 , after the close of the financial markets.  Company management will host a live audio webcast immedia...